1. Abrams, D. N., Knaus, E. E., McQuarrie, S. A., and Wiebe, L. I. (1978). [18F] 5-fluoro-2’-deoxy uridine as a radiopharmaceutical for diagnostic oncology. The Chemistry of Radiopharmaceuticals, N. D. Heindel, H. D. Burns, T. Honda, and L. W. Brady, eds. New York: Masson, pp. 205–213.
2. Abrams, D. N., Knaus, E. E., and Wiebe, L. I. (1979a). Tumor uptake of radiolabeled pyrimidine bases and pyrimidine nucleosides in animal models I. 6-[3H]-5-fluorouracil. Int. J. Nucl. Med. Biol. 6: 97–101.
3. Abrams, D. N., Knaus, E. E., and Wiebe, L. I. (1979b). Tumor uptake of radiolabeled pyrimidine bases and pyrimidine nucleosides in animal models II. 6-[3H]-5-fluoro-2’-deoxyuridine. Int. J. Nucl. Med. Biol. 6: 103–107.
4. Abrams, D. N., Knaus, E. E., Wiebe, L. I., Helus, F., and Maier-Borst, W. (1979c). Tissue uptake andexcretion of 2’-[123I]-iodo-2’-deoxyuridine in animal tumor models. Eur. J. Nucl. Med. 4: 134.
5. Abrams, D. N., Knaus, E. E., Wiebe, L. I., Helus, F., and Maier-Borst, W. (1981). Tumor uptake of radiolabeled pyrimidine bases and pyrimidine nucleosides in animal models. IV. 2’-123I-iodo-2’-deoxyuridine. Int. J. Appl. Radiat. Isot. 32: 105–108.